Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
S&P 500 closes higher on soft inflation report, Nasdaq jumps 1% as traders snap up tech shares
Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Pfizer appoints former J&J executive to lead obesity drug development
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
Dow tumbles 400 points, Nasdaq enters correction as trade policy fatigue ignites sell-off: Live updates
Stock futures are little changed Wednesday night after the major averages rebounded on hopes for concessions on President ...
manilatimes14d
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...
AstraZeneca opens biomethane plant in UK to cut emissions
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its research and development and drug manufacturing in Britain is powered by clean ...
NJBIZ16d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...
MarketWatch16d
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...
Euroinvestor16d
Novo Nordisk-aktien stiger markant: 'Det er mere end blot noget'
Novo Nordisk-aktien stiger markant i tirsdagens aktiehandel og er i skrivende stund oppe med 4,5 pct. Dermed er Novo Nordisk-aktien steget 17 pct. på en uge. »Det er mere end blot ”noget”,« lyder ...
Wall Street Journal17d
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...
Nasdaq20d
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).